Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06469853Phase 2Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients

Role: lead

NCT05940558Phase 2Completed

Safety and Efficacy of MBF-118 in Patients with Crohn Disease

Role: lead

NCT05940571Phase 1Completed

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

Role: lead

NCT05921916Phase 1Completed

Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers

Role: lead

NCT06049147Phase 1Completed

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

Role: lead

All 5 trials loaded